Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732625 | 0.83 | LMNA (0.38) | ALDH1A1L3MBTL1FAAHSRD5A1LMNA | |
| SCHEMBL5733122 | 0.78 | RXFP1 (0.39) | ALDH1A1NR1I2SMN1; SMN2LMNAPOLB | |
| SCHEMBL5732978 | 0.74 | SMN1; SMN2 (0.37) | ALDH1A1L3MBTL1SMN1; SMN2NPC1TP53 | |
| SCHEMBL5733074 | 0.73 | L3MBTL1 (0.47) | ALDH1A1L3MBTL1HPGDSMN1; SMN2LMNA | |
| SCHEMBL5732716 | 0.73 | KDM4E (0.45) | ALDH1A1FAAHLMNAPOLBNPC1 | |
| SCHEMBL23684304 | 0.73 | UNG (0.53) | HPGDSRD5A1SMN1; SMN2LMNARAB9A | |
| SCHEMBL5734228 | 0.72 | CYP4F2 (0.42) | SMN1; SMN2LMNAPOLBNPC1TP53 | |
| SCHEMBL5732673 | 0.71 | CES2 (0.51) | ALDH1A1HPGDSMN1; SMN2POLBNPC1 | |
| SCHEMBL5734479 | 0.71 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1HPGDLMNAPOLB | |
| SCHEMBL5733422 | 0.71 | RAB9A (0.51) | ALDH1A1L3MBTL1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1409455-A1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | PTGER4, FFAR4, PTGER1 | ALDH1A1 569/4885L3MBTL1 2782/4885HPGD 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.